# TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

> **NCT03179904** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 17 (actual)

## Conditions studied

- Advanced Breast Carcinoma
- HER2-Positive Breast Carcinoma
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Denifanstat
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant
- **PROCEDURE:** Echocardiography
- **DRUG:** Letrozole
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Trastuzumab
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT03179904
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-03
- **Primary completion:** 2024-07-30
- **Final completion:** 2026-06-13
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179904, "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03179904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*